Johnson & Johnson Defined Benefit Plan, Ultimate Health Care Cost Trend Rate
Johnson & Johnson (JNJ) had Defined Benefit Plan, Ultimate Health Care Cost Trend Rate of 4.01% as of 2025-12-28, per its 10-K filed 2026-02-11.
Financial Statements › Notes › Compensation Related Costs › Defined Benefit Plan › Defined Benefit Plan, Assumed Health Care Cost Trend Rates
us-gaap:DefinedBenefitPlanUltimateHealthCareCostTrendRate1 · last filed 2026-02-11
- 2025-12-28: Defined Benefit Plan, Ultimate Health Care Cost Trend Rate 4.01%.
- 2024-12-29: Defined Benefit Plan, Ultimate Health Care Cost Trend Rate 4.02%.
- 2023-12-31: Defined Benefit Plan, Ultimate Health Care Cost Trend Rate 4.00%.
- 2023-01-01: Defined Benefit Plan, Ultimate Health Care Cost Trend Rate 3.99%; Defined Benefit Plan, Ultimate Health Care Cost Trend Rate as first filed 4.01%.
| Period end | Defined Benefit Plan, Ultimate Health Care Cost Trend Rate | Defined Benefit Plan, Ultimate Health Care Cost Trend Rate as first filed |
|---|---|---|
| 2025-12-28 | 4.01% 10-K · filed 2026-02-11 | |
| 2024-12-29 | 4.02% 10-K · filed 2026-02-11 | |
| 2023-12-31 | 4.00% 10-K · filed 2025-02-13 | |
| 2023-01-01 | 3.99% 10-K · filed 2024-02-16 | 4.01% 10-K · filed 2023-02-16 |
| 2022-01-02 | 3.73% 10-K · filed 2023-02-16 | |
| 2021-01-03 | 4.49% 10-K · filed 2022-02-17 | |
| 2019-12-29 | 4.50% 10-K · filed 2021-02-22 | |
| 2018-12-30 | 4.55% 10-K · filed 2020-02-18 | |
| 2017-12-31 | 4.55% 10-K · filed 2019-02-20 | |
| 2017-01-01 | 4.50% 10-K · filed 2018-02-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ELI LILLY & Co (LLY) | United States | $1,113.804B | 42.28 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |